Figure S1 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors

<p>Supplementary Figure S1. MAGeCK analysis of CRISPR screens – related to Figure 1. A) Volcano plots showing MAGeCK analysis of CRISPR-Cas9 screens performed in BRCA1 wildtype cancer cell lines, A549 (left) and CAL27 (right). Genes on the left are depleted and genes on the right are enriched in olaparib treatment compared to DMSO treatment. B) Volcano plots showing MAGeCK analysis of CRISPR-Cas9 screens performed in DLD-1 WT (left) and DLD-1 BRCA2 het (right) cells. Genes on the left are depleted and genes on the right are enriched in olaparib treatment compared to DMSO treatment. C) Volcano plots showing MAGeCK analysis of CRISPR-Cas9 screens performed in DLD-1 BRCA2 mutant (left) and DLD-1 BRCA2 null (right) cells. Genes on the left are depleted and genes on the right are enriched in olaparib treatment compared to DMSO treatment.</p>

Authors

Publication Details

Published
2025-09-02
DOI
https://doi.org/10.1158/1535-7163.30028940
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Figure S1 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors

Brian Doyon, Madhavi Bandi, Tianshu Feng, William D. Mallender et al.
PARP inhibition in cancer therapy
article

Figure S1 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors

Brian Doyon, Madhavi Bandi, Tianshu Feng, William D. Mallender, Robert Tjin Tham Sjin, Jannik N. Andersen, Erik Wilker, Douglas A. Whittington, Alan Huang, Yi Yu, Xuewen Pan, Katherine Lazarides, Shangtao Liu, Hongxiang Zhang, Ashley H. Choi, Justin L. Engel, Binzhang Shen, Samuel R. Meier, Brian J. McMillan, Michele Meseonznik
article en

Abstract

<p>Supplementary Figure S1. MAGeCK analysis of CRISPR screens – related to Figure 1. A) Volcano plots showing MAGeCK analysis of CRISPR-Cas9 screens performed in BRCA1 wildtype cancer cell lines, A549 (left) and CAL27 (right). Genes on the left are depleted and genes on the right are enriched in olaparib treatment compared to DMSO treatment. B) Volcano plots showing MAGeCK analysis of CRISPR-Cas9 screens performed in DLD-1 WT (left) and DLD-1 BRCA2 het (right) cells. Genes on the left are depleted and genes on the right are enriched in olaparib treatment compared to DMSO treatment. C) Volcano plots showing MAGeCK analysis of CRISPR-Cas9 screens performed in DLD-1 BRCA2 mutant (left) and DLD-1 BRCA2 null (right) cells. Genes on the left are depleted and genes on the right are enriched in olaparib treatment compared to DMSO treatment.</p>

Openalex Percentile: Top 68%
PARP inhibition in cancer therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.